Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
about
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.The role of laminins in the organization and function of neuromuscular junctions.Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A.New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease.Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
P2860
Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Complete reversal of Lambert-E ...... er and a Ca2+ channel agonist.
@ast
Complete reversal of Lambert-E ...... er and a Ca2+ channel agonist.
@en
type
label
Complete reversal of Lambert-E ...... er and a Ca2+ channel agonist.
@ast
Complete reversal of Lambert-E ...... er and a Ca2+ channel agonist.
@en
prefLabel
Complete reversal of Lambert-E ...... er and a Ca2+ channel agonist.
@ast
Complete reversal of Lambert-E ...... er and a Ca2+ channel agonist.
@en
P2093
P2860
P1476
Complete reversal of Lambert-E ...... er and a Ca2+ channel agonist.
@en
P2093
David Lacomis
Guillermo Valdomir
Mary Liang
Michael Frasso
Stephen D Meriney
Stephen W Reddel
Tyler B Tarr
P2860
P304
P356
10.1113/JPHYSIOL.2014.276493
P407
P50
P577
2014-07-11T00:00:00Z